Satellite Banner
Technology Networks Header
Wednesday, October 01, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Epigenetic Variation as a Driver of Breast Cancer Risk
  Videos

Return

Epigenetic Variation as a Driver of Breast Cancer Risk
Imperial College London

Genetic epidemiology aims to use the natural variation in the genome to look for associations between particular genotypes and disease risk or prognosis. Epigenetic epidemiology, a new area of research, aims to address the same questions about disease risk and prognosis using the natural variation present in the epigenome. It is now apparent that the variation between individuals does not occur at the classical promoter CpG island, but in other areas of the gene and that these regions are yielding markers of both cancer risk and prognosis. We have identified a breast cancer risk marker in the ATM gene using blood samples collected from prospective cohorts. We have also analysed blood samples from an ovarian cancer clinical trial, SCOTROC1, to identify prognostic biomarkers of progression free survival, overall survival, response and toxicity. Lastly, we have also shown that cancer risk exposures, such as smoking, can affect the epigenome detectable in blood DNA and may provide a more accurate measure of long term exposures. These studies, therefore, support the hypothesis that epigenetic variation may be a driver of cancer risk or prognosis.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Chemists Recruit Anthrax to Deliver Cancer Drugs
With some tinkering, a deadly protein becomes an efficient carrier for antibody drugs.
Biologists Find An Early Sign Of Cancer
Patients show boost in certain amino acids years before diagnosis of pancreatic cancer.
Protein ‘Map’ Could Lead to Potent New Cancer Drugs
Findings will help scientists to design drugs that could target NMT enzyme.
New Approach Aims to Silence Cancer ‘Survival Genes’
Scientists at the University of York are working on a promising new approach for tackling colorectal cancer, the second most common cause of cancer-related death.
DNA in ‘Gene Deserts’ Linked with Breast Cancer
Non-coding DNA raised the risk of breast cancer by affecting the activity of key genes.
Inivata Raises £4m to Realize the Potential of ctDNA Analysis
New spin-out from Cancer Research UK launched with funding from Imperial Innovations, Cambridge Innovation Capital and Johnson & Johnson Development Corporation.
Reversing The Effects Of Pulmonary Fibrosis
Study shows potential for reversing the effects of pulmonary fibrosis with a microRNA mimic.
Gene Expression Patterns in Pancreatic CTCs Revealed
Distinct patterns of gene expression in several groups of CTCs were identified, including significant differences from the primary tumor that may contribute to the ability to generate metastases and prove to be targets for improved treatment of the deadly tumor.
Promise for Treatment of Pancreatic Cancer
Ultrasound microbubbles can improve tumor absorption of cancer drugs.
Novel Drug Targeting Leukemia Cells Enters Clinical Trial
Phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for CLL patients.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv